Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$191.51 - $216.16 $2.26 Million - $2.55 Million
11,814 Added 35.17%
45,404 $9.63 Million
Q2 2023

Aug 14, 2023

BUY
$187.64 - $206.25 $2.27 Million - $2.49 Million
12,072 Added 56.1%
33,590 $6.46 Million
Q1 2023

May 15, 2023

BUY
$127.59 - $203.08 $2.52 Million - $4.01 Million
19,759 Added 1123.31%
21,518 $4.36 Million
Q4 2022

Feb 14, 2023

SELL
$117.37 - $139.17 $825,932 - $979,339
-7,037 Reduced 80.0%
1,759 $226,000
Q3 2022

Nov 14, 2022

SELL
$135.27 - $180.11 $318,019 - $423,438
-2,351 Reduced 21.09%
8,796 $1.2 Million
Q2 2022

Aug 15, 2022

BUY
$108.81 - $179.33 $1.21 Million - $2 Million
11,147 New
11,147 $1.97 Million
Q2 2021

Aug 16, 2021

SELL
$135.08 - $161.1 $289,071 - $344,754
-2,140 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$137.51 - $190.8 $294,271 - $408,312
2,140 New
2,140 $297,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.